Used in targeted cancer therapies, particularly for tumors expressing EphA3, a receptor involved in cell signaling and tumor progression. Binds specifically to EphA3 on cancer cells, enabling immune-mediated destruction or delivery of cytotoxic agents. Investigated in hematologic malignancies and solid tumors due to EphA3 overexpression in certain leukemias and cancers. Supports antibody-dependent cellular cytotoxicity (ADCC) and can be engineered for use in antibody-drug conjugates (ADCs) to enhance tumor-specific killing while minimizing damage to healthy tissues. Also serves as a research tool to study Eph/ephrin signaling pathways in development and disease.